Apollo to Announce Fourth Quarter and Full Year 2025 Financial Results on February 9, 2026

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) plans to release financial results for the fourth quarter and full year 2025 on Monday, February 9, 2026, before the opening of trading on the New York Stock Exchange. Management will review Apollo’s financial results at 8:30 am ET via public webcast available on Apollo’s Investor Relations website at ir.apollo.com. A replay will be available one hour after the event.

Apollo distributes its earnings releases via its website and email lists. Those interested in receiving firm updates by email can sign up for them here.

About Apollo

Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of September 30, 2025, Apollo had approximately $908 billion of assets under management. To learn more, please visit www.apollo.com.

Contacts

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
[email protected]

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
[email protected]



Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. In addition, the Company announced that its management team will participate in the 15th LifeSci Partners Corporate Access event taking place January 12-14, 2026, in San Francisco, California.

“As we reflect on the data generated with lorundrostat to date, we are more confident than ever of the drug candidate’s best-in-class profile, based on the clinically meaningful blood pressure reduction, the demonstrated 24-hour control, its benefit across the spectrum of difficult-to-treat patients, and its safety and tolerability profile,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “We look forward to reporting the Explore-OSA data in the first quarter of 2026, which we expect will further support our strategy to extend lorundrostat’s profile in treating patients with hypertension and comorbid conditions.”

Recent Clinical Highlights and Upcoming Milestones:

  • Explore-OSA Phase 2 Trial – The Company remains on track to report topline results from the Phase 2 Explore-OSA trial in the first quarter of 2026. Enrollment was completed in the third quarter of 2025, and the trial is evaluating the benefits of lorundrostat on symptoms of OSA and blood pressure in participants with hypertension and moderate to severe OSA.  
  • Lorundrostat New Drug Application (NDA) – Mineralys filed an NDA for lorundrostat to the U.S. Food and Drug Administration (FDA) in late 2025. The submission followed a successful clinical program, which culminated in the completion of three positive clinical trials of lorundrostat in 2025. In these trials, lorundrostat demonstrated best-in-class safety and 24-hour blood pressure control across a spectrum of distinct and diverse patient populations.
  • Transform-HTN Open-Label Extension Trial – The Company’s ongoing open-label extension trial, which supported the NDA submission, enables participants to continue to receive lorundrostat and allows the Company to gather additional long-term safety and efficacy data.
  • Explore-CKD Phase 2 Trial – Mineralys announced positive data from the Phase 2 Explore-CKD trial evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension, reduced kidney function and albuminuria. The crossover trial met its primary endpoint on systolic blood pressure reduction and demonstrated meaningful reduction in proteinuria.
  • Pivotal Launch-HTN Phase 3 Trial – The global trial met its primary endpoint in evaluating the efficacy and safety of lorundrostat for the treatment of participants with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as add-on therapy, who fail to achieve blood pressure (BP) control on their existing medications.
  • Pivotal Advance-HTN Trial – The trial met its primary endpoints in evaluating the efficacy and safety of lorundrostat for the treatment of confirmed uHTN or rHTN on top of optimized, standardized AHA guideline background medications. These results reinforce lorundrostat’s favorable benefit-risk profile in a high-risk population that would typically be treated by specialists rather than general practitioners.

About Lorundrostat

Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uHTN or rHTN, as well as CKD and OSA. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants.

The Company has now completed four successful clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The Company has completed two pivotal, registrational trials, including the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic BP by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedInTwitter and Bluesky.

Forward Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company’s expectation that Advance-HTN and Launch-HTN may serve as pivotal trials in submission of an NDA to the FDA; the anticipated timing of the FDA’s review of our NDA submission; the Company’s ability to evaluate lorundrostat as a potential treatment for CKD, OSA, uHTN or rHTN; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of participants in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA following submission of an NDA; any delays in the FDA’s review of our NDA submission, including as a result of a government shutdown or reductions in agency funding or personnel, the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for an NDA submission or regulatory approval of lorundrostat; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations

[email protected]

Media Relations

Melyssa Weible
Elixir Health Public Relations
Email: [email protected]



Heartflow Plaque Analysis Now Covered by Aetna Insurance Plans Nationwide and for the Majority of Insured Lives in the U.S.

Fourth major national payer releases positive comprehensive coverage for AI-powered Heartflow Plaque Analysis

MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans. Aetna is the fourth major national commercial insurer to update its policies to cover Heartflow Plaque Analysis to fully align with the guidelines issued by radiology benefit manager EviCore, following similar decisions by Humana, Cigna, and UnitedHealthcare. Heartflow Plaque Analysis is covered for the majority of insured lives across the United States.

This coverage milestone follows the American Medical Association’s recent implementation of the new Category I Current Procedural Terminology (CPT®) payment code 75577 for Heartflow Plaque Analysis, effective January 1, 2026, which established 0.85 relative value units (RVUs) and a combined total of 4.00 RVUs for physicians performing the service.

“Aetna’s decision to cover Heartflow Plaque Analysis nationwide is a pivotal step in expanding access to our AI-driven plaque quantification and characterization technology,” said John Farquhar, President and CEO of Heartflow. “With four major commercial payers and Medicare now recognizing the innovation and value of our platform, more clinicians can gain earlier, clearer insights into coronary plaque. More patients will benefit from early detection and precise quantification of plaque with Heartflow Plaque Analysis, leading to more personalized treatment strategies and improved prognostic assessment, helping set a new benchmark for cardiovascular care.”

The updated coverage became effective on December 23, 2025 for Aetna patients with acute or stable chest pain and mild-to-moderate narrowing of coronary arteries (1-69% stenosis) identified on coronary CTA. The policy expands access for patients to AI-driven plaque analysis, supporting earlier diagnosis, personalized risk stratification, and more precise management of CAD.

The new CPT code was issued in response to increased utilization of AI-powered plaque quantification and characterization technology like Heartflow Plaque Analysis and strong clinical evidence supporting its value. Together, broader national payer coverage and Category I reimbursement position the Heartflow platform as the highest-value pathway in cardiac CT, expanding access and supporting practical adoption in clinical practice.

Heartflow’s continued advancement of Heartflow Plaque Analysis builds on the real-world evidence demonstrated in the landmark DECIDE Registry data, the largest prospective registry evaluating the clinical impact of Heartflow Plaque Analysis on medical management decisions. The DECIDE registry showed that more than 50% of patients had their medical management changed when Heartflow Plaque Analysis with Heartflow Plaque Staging* was added compared to their management based on CCTA alone.1 A retrospective analysis of symptomatic patients from a cohort of the FISH&CHIPS Study presented at the AHA Scientific Sessions 2025 provided the largest validation to date of the Heartflow Plaque Staging framework based on total plaque volume measurement as a predictor of future heart attacks or cardiovascular death.2

Heartflow Plaque Analysis is the only FDA-cleared, AI-powered plaque quantification tool with 95% agreement to the gold standard, IVUS, using blinded core lab adjudication.3

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide.4 Key benefits include:

  • Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
  • Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
  • Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
  • Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Media Contact

Elliot Levy
[email protected]

Investor Contact

Nick Laudico
[email protected]



1
DECIDE Registry. Rinehart, et al., presented at SCCT 2025.
2 Fairbairn et al., presented at AHA 2025.
3 Ihdayhid A, et al. Radiol Cardiothorac Imaging. 2024. doi: 10.1148/ryct.230312 and internal bridging study with ICC correlation between first generation and second generation Plaque Analysis algorithm.
4 Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol.
*Heartflow Plaque Analysis is an FDA-cleared device. Heartflow Plaque Staging is an investigational-only framework, and its safety and effectiveness have not been reviewed by the FDA.



Synchronoss Showcases Expanded Personal Cloud Platform, Capsyl Momentum, and Previews New Offering at CES 2026

Advancing Personal Cloud Capabilities for Operators and Consumers

BRIDGEWATER, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader and innovator in personal cloud solutions, today announced expanded capabilities across its white-label Synchronoss Personal Cloud platform at CES 2026 in Las Vegas. The company is also highlighting continued momentum for Capsyl, its turnkey personal cloud solution, and previewing a new event-based digital experience focused on shared moments and group engagement.

Expanded Synchronoss Personal Cloud Platform Capabilities

At CES, Synchronoss is showcasing new enhancements to its white-label Personal Cloud platform designed to help operators and brands deliver secure, scalable, and differentiated cloud services. Updates strengthen core content management, cross-device backup and sync, and cloud intelligence, while introducing enhanced privacy and security controls such as locked folders for sensitive content, granular access and sharing permissions, and integrated document scanning capabilities for securely storing physical documents.

Capsyl Momentum and Market Expansion

Synchronoss is also highlighting continued progress for Capsyl, its hosted and fully managed personal cloud solution designed for rapid deployment by service providers and consumer brands. Capsyl delivers premium personal cloud capabilities out of the box, including cross-device access, curated memories, and AI-powered content tools, with minimal operational complexity.

On the 1-year anniversary following a successful market launch, Capsyl is expanding beyond its initial mobile footprint to support additional access types and consumer protection use cases, including fixed broadband and integrated security capabilities. This expansion enables broader household and multi-device experiences and reflects growing demand for turnkey cloud services that combine premium features, localization, and fast time to market.

Previewing a New Event-Based Group Experience App

In addition to platform updates and commercial momentum, Synchronoss is offering an early preview of a new cloud-powered concept designed around events and group experiences. Built on the Synchronoss cloud platform, the concept introduces event-specific cloud spaces that bring photos, videos, and related content together in one place, making it easy for people to contribute, access, and revisit content tied to trips, celebrations, live events, or group activities.

The experience is being explored for direct-to-consumer use, as well as future distribution or integration through strategic partners. The preview illustrates how personal cloud can evolve beyond static storage to better support how people capture, organize, and remember experiences together, while maintaining strong security and privacy controls.

“This year at CES, we are demonstrating how Synchronoss continues to strengthen the foundation of our cloud platform while expanding how it can be used and experienced,” said Jeff Miller, President and CEO of Synchronoss Technologies. “From enhanced security and intelligence across our platform, to growing momentum for our Capsyl solution, to previewing new ways cloud can support shared experiences, we are focused on helping our partners deliver trusted, meaningful services to their customers.”

About Synchronoss 

Synchronoss Technologies (Nasdaq: SNCR), a global leader in personal cloud solutions, empowers service providers to establish secure and meaningful connections with their subscribers. Our SaaS cloud platform simplifies onboarding processes and fosters subscriber engagement using artificial intelligence (AI), machine learning, and other advanced features, resulting in enhanced revenue streams, reduced expenses, and faster time-to-market. Millions of subscribers trust Synchronoss to safeguard their most cherished memories and important digital content. Explore how our cloud-focused solutions redefine the way you connect with your digital world at www.synchronoss.com.

Media Relations Contact: 
Domenick Cilea 
Springboard 
[email protected] 

Investor Relations Contact: 
Ryan Gardella 
ICR INC. 
[email protected] 



Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor meetings at the following January 2026 investor conferences.

Sachs Associates 9

th

Annual Neuroscience Innovation Forum

Company Presentation

Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: Sunday, January 11, 2026
Place: Marines’ Memorial Club & Hotel, San Francisco, Calif.
Time: 11:55 a.m. PT
Room: Track A, Rosenberg Room

Sachs Associates 9

th

Annual Neuroscience Innovation Forum

Panel

Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Title: Innovation in Neuropsychiatric Drug Development Panel
Date: Sunday, January 11, 2026
Place: Marines’ Memorial Club & Hotel, San Francisco, Calif.
Time: 1:15 p.m. PT

Biotech Showcase 2026

Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: Tuesday, January 13, 2026
Place: Hilton San Francisco Union Square, San Francisco, Calif.
Time: 11:00 a.m. PT
Room: Yosemite C
A replay of the presentation will be available on the Tonix website at www.tonixpharma.com following the presentation.

Investors interested in arranging a meeting with the Company’s management during these conferences should contact: [email protected]

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix markets FDA-approved TONMYATM, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. TONMYA is the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. TONMYA was investigated as TNX-102 SL. Tonix also markets two treatments for acute migraine in adults: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray). Tonix’s development portfolio* is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a Phase 2- ready Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study in 2026. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a Phase 2- ready long-acting humanized monoclonal antibody for the seasonal prevention of Lyme disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of high lethality infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication under development.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts

Jessica Morris 
Tonix Pharmaceuticals 
[email protected] 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
[email protected] 

Media Contacts

Mary Ann Ondish
[email protected]
(862) 799-8599

Ray Jordan 
Putnam Insights 
[email protected] 
 

INDICATION

TONMYA is indicated for the treatment of fibromyalgia in adults.

CONTRAINDICATIONS

TONMYA is contraindicated:
In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.

With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.

During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

In patients with hyperthyroidism.

WARNINGS AND PRECAUTIONS

Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.

Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.

Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.

Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.

CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.

Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS

MAO inhibitors: Life-threatening interactions may occur.

Other serotonergic drugs: Serotonin syndrome has been reported.

CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.

Tramadol: Seizure risk may be enhanced.

Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).

Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of TONMYA have not been established.

Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.

Please see additional safety information in the full Prescribing Information.

To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.



Levi & Korsinsky Notifies Shareholders of Stride, Inc.(LRN) of a Class Action Lawsuit and an Upcoming Deadline

PR Newswire

NEW YORK, Jan. 2, 2026 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Stride investors who were adversely affected by alleged securities fraud between October 22, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form-3?prid=182255&wire=4

LRN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that Stride was (1) inflating enrollment numbers by retaining “ghost students”; (2) cutting staffing costs by assigning teachers’ caseloads far beyond the required statutory limits; (3) ignoring compliance requirements, including background checks and licensure laws for its employees, and ignoring federally mandated special education services to students; (4) suppressing whistleblowers who documented financial directives from Stride’s leadership to delay hiring and deny services to preserve profit margins; and (5) losing existing and potential enrollments.

WHAT’S NEXT? If you suffered a loss in Stride during the relevant time frame, you have until January 12, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected] 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-notifies-shareholders-of-stride-inclrn-of-a-class-action-lawsuit-and-an-upcoming-deadline-302651429.html

SOURCE Levi & Korsinsky, LLP

Skyward Specialty Announces Completion of Apollo Acquisition

HOUSTON, Jan. 02, 2026 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD) (“Skyward Specialty” or the “Company”), today announced that it has completed its acquisition of Apollo Group Holdings Limited (“Apollo”) at the previously agreed upon terms.

About Skyward Specialty

Skyward Specialty is a rapidly growing and innovative specialty insurance company, delivering commercial property and casualty products and solutions on a non-admitted and admitted basis. The Company operates through nine underwriting divisions – Accident & Health, Agriculture and Credit (Re)insurance, Captives, Construction & Energy Solutions, Global Property, Professional Lines, Specialty Programs, Surety and Transactional E&S. SKWD stock is traded on the Nasdaq Global Select Market, which represents the top fourth of all Nasdaq listed companies.

Skyward Specialty’s insurance companies consist of Houston Specialty Insurance Company, Imperium Insurance Company, Great Midwest Insurance Company, and Oklahoma Specialty Insurance Company. These insurance companies are rated A (Excellent) with stable outlook by A.M. Best Company. Additional information about Skyward Specialty can be found on our website at www.skywardinsurance.com.

About Apollo

Apollo, a U.K. subsidiary of Skyward Specialty, is an innovation inspired insurance platform operating at Lloyd’s of London, offering data-driven and creative solutions to a wide variety of risks. The business provides high quality products and services to clients, and capital partners, enabling a resilient and sustainable world. Apollo offers products across Property, Casualty, Marine, Energy & Transportation, Specialty, Reinsurance, as well as Smart Follow and digital & embedded risk programs. Apollo’s experience and unique ecosystem give Platform Partners the best chance of success through the Lloyd’s new entrant process to the delivery of their long-term strategy. For more information about Apollo, please visit apollounderwriting.com.

Forward Looking Statements

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “expect,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change, or other circumstance that could give rise to the right of one or both parties to terminate the definitive transaction agreement, the possibility that the anticipated benefits and synergies of the proposed transaction are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas when Skyward Specialty and Apollo do business, the diversion of management’s attention from ongoing business operations and opportunities, potential adverse reactions or changes to business or employee relationships, as well as described in Skyward Specialty’s Form 10-K, and include (but are not limited to) legislative changes at both the state and federal level, state and federal regulatory rule making promulgations and adjudications, class action litigation involving the insurance industry and judicial decisions affecting claims, policy coverages and the general costs of doing business, the potential loss of key members of our management team or key employees and our ability to attract and retain personnel, the impact of competition on products and pricing, inflation in the costs of the products and services insurance pays for, product development, geographic spread of risk, weather and weather-related events, other types of catastrophic events, our ability to obtain reinsurance coverage at prices and on terms that allow us to transfer risk and adequately protect our company against financial loss, and losses resulting from reinsurance counterparties failing to pay us on reinsurance claims. These forward-looking statements speak only as of the date of this release and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

Investor Contact

Kevin Reed
Skyward Specialty Insurance Group
713-206-7860
[email protected]

Media Contacts

Skyward Specialty Insurance Group
Haley Doughty
713-935-4944
[email protected]

Apollo
Haggie Partners
Peter Rigby, Caroline Klein, Bec Seaton
44 20 7562 4444
[email protected]

This press release was published by a CLEAR® Verified individual.



UPDATE — OBOOK Holdings Inc. (OWLS) issues Year-End CEO Letter to Shareholders

ARLINGTON, Va., Dec. 23, 2025 (GLOBE NEWSWIRE) —  OBOOK Holdings Inc. (NASDAQ: OWLS) (the “Company” or “OwlTing”) today issued Year-End Letter to Shareholders from its Founder and CEO, Darren Wang.

Dear Shareholders,

I have spent the past twelve years in the blockchain industry.

Over that time, I have witnessed multiple waves of technological change — and I have seen the same technology lead to very different outcomes. Some chose to chase market momentum and short-term gains. Others chose to invest their time and resources in work that was less visible, but built to endure.

During these twelve years, the question I have been asked most often is simple: “Why not move faster?”

It is a fair question, and one we have thought about deeply.

From the very beginning, I made a deliberate choice. I did not want to build increasingly complex, well-packaged financial products. I wanted to solve a real problem — one that exists in everyday life, yet has never been properly addressed.

A Problem Everyone Has Experienced

Consider a simple, familiar situation.

In 2025, sending a WhatsApp message to someone on the other side of the world takes one second and costs nothing. Yet sending money to that same place often takes days and comes with meaningful fees.

Why can information move instantly, while money cannot? Why can’t money move as easily as a message?

This is not a technological limitation. The technology required for real-time value transfer has existed for years. The real constraint is responsibility.

Every movement of money carries obligations—anti-money-laundering requirements, source-of-funds verification, consumer protection, financial stability, and coordination across regulatory systems. For good reason, money must move within strict legal and licensing frameworks.

We do not view these frameworks as unreasonable barriers. On the contrary, they are what make financial systems trustworthy over the long term.

The true challenge is not bypassing regulation, but operating within it while meaningfully improving speed, cost, and reliability.

That challenge is precisely why OwlTing exists.

Long-Term Value as Our North Star

We believe the ultimate measure of our success is whether we create long-term value for our shareholders—much like Amazon, whose focus has always remained on durable, long-term outcomes.

That value comes from raising competitive barriers, entering markets early, and building positions that can be sustained over time. A strong global footprint enables higher-quality revenue, more stable cash flows, and more efficient capital deployment.

Because we take a long-term view, many of our decisions—and the way we evaluate trade-offs—differ from those of other companies. We believe it is important to share this philosophy clearly with our shareholders:

  1. We remain uncompromising in our compliance-first, technology-driven approach, and we open these standards and capabilities to companies across industries to help them grow responsibly.
  2. Our investment decisions are guided by long-term market leadership, not short-term profitability or market reactions.
  3. We operate with disciplined cost management while preserving a builder’s culture, recognizing that financial resilience depends on operational rigor.
  4. We prioritize hiring exceptional talent and emphasize equity ownership over cash compensation, because great people ultimately determine long-term shareholder value.

These principles have guided our development for more than a decade, and they continue to define how we operate today.

Looking Back: Slow, but Built to Last

Over the past five years, we deliberately chose a slower—but structurally sound—path. Nearly every major decision came down to one question: Will this still make sense five or ten years from now?

Rather than chasing visibility or momentum, we focused on fundamentals: building systems correctly, completing licensing frameworks, and laying infrastructure designed for long-term use.

Over the past year in particular, we intentionally slowed down further to deepen our foundation. Most of our time and resources were dedicated to two areas that may not attract attention—but ultimately define long-term potential.

1.   Building the Rails for Money Movement

We chose to work with the most established and reliable partners in the financial ecosystem, rather than taking shortcuts.

Through our integration with Visa Direct, we expanded the role of card networks. Historically, cards were primarily tools for spending. Today, they can also be used to receive and move funds — allowing individuals and businesses to participate in cross-border money movement through existing card infrastructure.

At the same time, we integrated Stellar and the Circle Payments Network (CPN) and partnered with Cross River Bank, enabling USDC to move compliantly, in real time, and 24/7 between blockchain networks and the traditional banking system.

These integrations are not flashy. But they make stablecoins usable in real financial workflows — where repeat usage by banks and enterprises truly matters.

2.   Completing the Compliance “Passport”

If technology is the rail, compliance is the passport. Without it, even the fastest system cannot enter the mainstream financial system.

We have invested more than four years—and significant resources—building this foundation:

In the United States, we maintain money transmitter licenses (MTLs) in 39 states, covering the vast majority of major U.S. markets, and continue to expand and update our regulatory footprint as requirements evolve.

In Japan, we currently hold one API-based funds transfer license, with two additional payment and remittance licenses under active review.

In Europe, we hold a VASP license and are progressing with regulatory upgrades and consolidation.

These licenses are among OwlTing’s quietest assets — but also its most critical. They determine not only what we are permitted to do, but whether institutions can trust us and adopt our infrastructure over time.

Our Focus for 2026: Lowering the Barrier to Stablecoin Access

As the foundation comes into place, our next priority is not adding complexity — but removing friction.

We want businesses and consumers to benefit from the speed and cost efficiency of stablecoins through familiar tools, whether debit cards or credit cards, without needing to understand the underlying infrastructure.

The user experience does not need to change. What changes is the settlement speed, cost structure, and reliability behind the scenes.

OwlTing is building financial infrastructure.

Like subways or highways, much of the work remains invisible until enough people rely on it. That is when the value becomes clear.

We cannot promise that every step will generate headlines. But we can promise that our decisions are made with the next decade in mind — and that they are built to withstand scrutiny over time.

If you are willing to take a longer-term view of this journey, we are deeply grateful for your trust.

The real challenge is not getting started. It is becoming something others can depend on.

2025 was a meaningful year for OwlTing. We completed a major transition in our business model and clarified the long-term path we are building toward. We are sincerely thankful to our users and shareholders—our progress this year and in the years ahead would not be possible without your support.

This is still Day 1.

Darren Wang

Founder & Chief Executive Officer

OwlTing Group (OBOOK Holdings Inc.)

About OBOOK Holdings Inc. (OwlTing Group)

OBOOK Holdings Inc. (NASDAQ: OWLS) is a blockchain technology company operating as the OwlTing Group. The Company was founded and is headquartered in Taiwan, with subsidiaries in the United States, Japan, Poland, Singapore, Hong Kong, Thailand, and Malaysia. The Company operates a diversified ecosystem across payments, hospitality, and e-commerce. In 2025, according to CB Insights’ Stablecoin Market Map, OwlTing was ranked among the top 2 global players in the “Enterprise & B2B” category. The Company’s mission is to use blockchain technology to provide businesses with more reliable and transparent data management, to reinvent global flow of funds for businesses and consumers and to lead the digital transformation of business operations. To this end, the Company introduced OwlPay, a Web2 and Web3 hybrid payment solution, to empower global businesses to operate confidently in the expanding stablecoin economy. For more information, visit https://www.owlting.com/portal/?lang=en.

Safe Harbor Statement

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “aim,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “likely,” “potential,” “project,” or “continue,” or the negative of these terms or other comparable terminology. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that such expectations will prove correct. The Company cautions investors that actual results may differ materially from those anticipated and encourages investors to review other factors that may affect its future results in the Company’s registration statement filed with and declared effective by the SEC and other filings with the SEC, available at www.sec.gov.

OBOOK Holdings Inc. Media Relations

Michael Hsu, Public Relations Director
[email protected]



The Hyatt Centric Brand Debuts in Puerto Rico with Hyatt Centric San Juan Isla Verde

The Hyatt Centric Brand Debuts in Puerto Rico with Hyatt Centric San Juan Isla Verde

The renovated hotel provides the perfect home base for exploring Puerto Rico’s vibrant coastline, rich culture, and local hidden gems

CHICAGO–(BUSINESS WIRE)–Hyatt Hotels Corporation (NYSE: H), Interlink and Vivo Beach Club today announced the opening of Hyatt Centric San Juan Isla Verde, marking the first Hyatt Centric branded hotel in Puerto Rico. Located in one of Puerto Rico’s most celebrated neighborhoods, the hotel is walking distance to the award-winning Isla Verde Beach, vibrant restaurants, nightlife, and shopping, placing savvy travelers in the middle of the action. A five-minute drive from Luis Muñoz Marin International Airport, the hotel provides easy access to the historic colonial district of Old San Juan, El Yunque National Rain Forest, San Juan’s Financial District, and the Puerto Rico Convention District.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217118616/en/

Lobby & Espresso Lab

Lobby & Espresso Lab

Following the completion of a $30-million-dollar transformation from the former Verdanza Hotel, the newly renovated Hyatt Centric San Juan Isla Verde features 223 thoughtfully designed guestrooms and suites with city and partial ocean views. The guestroom design draws inspiration from Puerto Rico’s natural beauty, including the surrounding Atlantic Ocean, Caribbean Sea, sea corals, and mountains—incorporating vibrant textures, contemporary touches, and locally inspired details that reflect the culture and spirit of the island. Lead interior design and architecture firms involved in the project include V Architecture, 3MG, Baskerville and landscape architect EDSA.

Enhancing the experience, guests can enjoy complimentary access and shuttle service to Vivo Beach Club, an oceanfront private beach club in a resort-like atmosphere designed for guests of all ages. The club features three pools, four restaurants and bars, the award-winning Ocean Lab Brewing Co. micro-brewery, and an outdoor concert stage with capacity for 3,500 people, recognized as one of the top music venues in Puerto Rico.

“The inauguration of Hyatt Centric San Juan Isla Verde marks a significant moment for tourism in Puerto Rico, the result of an exemplary collaboration between local talent, capital, and effort. This project—developed and remodeled entirely with Puerto Rican expertise—transforms a traditional hotel into a vibrant and unique concept, integrated for the first time with Vivo Beach Club to offer immersive experiences that bring together design, gastronomy, entertainment, and the beach. With renovated facilities, an exclusive beach club for guests, and a wide culinary, recreational, and cultural offering, the hotel positions itself as a new landmark for both locals and visitors, reaffirming Isla Verde’s potential and its contribution to the region’s economic development. We are deeply grateful to Hyatt for its commitment to the local market and to everyone who made this achievement possible, which is above all an investment in our people, our industry, and the future of Puerto Rico’s tourism sector,” said Federico J. Sánchez Ortiz, President & CEO of Interlink, and Luis and Matías Fernández, Owners of Vivo Beach Club; Co-Owners of Hyatt Centric San Juan Isla Verde.

The hotel offers a resort-style pool deck and jacuzzi with an open-air restaurant and bar, a 24-hour fitness center, and a kid-friendly splash pad. The hotel is also pet-friendly, welcoming four-legged companions with dedicated amenities.

Hyatt Centric San Juan Isla Verde is home to two distinct food and beverage experiences, including:

  • Alba – a full-service culinary experience inspired by Puerto Rican flavors, open from 6:30am – 10:00pm.
  • Espresso Lab – a coffee concept offering local favorites and artisanal selections, open from 6:30am – 6:00pm.

Renowned Puerto Rican chef, Efraín Cruz, is the hotel’s Executive Chef overseeing the culinary offering of each outlet, events and banquets.

With over 16,000 sq. ft. of indoor and outdoor meeting and event space, including a rooftop terrace with ocean views, the hotel offers versatile venues well-suited for corporate gatherings, social celebrations, and creative meetings. From intimate boardrooms to large ballrooms and open-air spaces with modern technology, each setting is designed with flexibility and creativity in mind.

Hyatt Centric San Juan Isla Verde marks the sixth Hyatt hotel in Puerto Rico, joining Hyatt Place San Juan and Hyatt House San Juan, Hyatt Place Bayamon, Hyatt Place Manati and Hyatt Regency Grand Reserve Puerto Rico. The hotel is managed by Highgate Hotels, an industry-leading hotel management firm, with a diverse portfolio of hotels across North America, the Caribbean, Latin America, and Europe, including three other hotels in Puerto Rico.

To celebrate the official opening, World of Hyatt is offering members the opportunity to earn 500 Bonus Points for qualifying nights at Hyatt Centric San Juan Isla Verde through March 31, 2026, part of World of Hyatt’s new hotel member offer. Additional participating hotels and their offer stay periods can be found at worldofhyatt.com/newhotelbonus. No registration is required and members can earn on top of other offers. Terms Apply.

For more information or to book a reservation, please visit www.hyattcentricsanjuanislaverde.com.

The term “Hyatt” is used in this release for convenience to refer to Hyatt Hotels Corporation and/or one or more of its affiliates.

About Hyatt Hotels Corporation

Hyatt Hotels Corporation, headquartered in Chicago, is a leading global hospitality company guided by its purpose – to care for people so they can be their best. As of September 30, 2025, the Company’s portfolio included more than 1,450 hotels and all-inclusive properties in 82 countries across six continents. The Company’s offering includes brands in the Luxury Portfolio, including Park Hyatt®, Alila®, Miraval®, Impression by Secrets, and The Unbound Collection by Hyatt®; the Lifestyle Portfolio, including Andaz®, Thompson Hotels®, The Standard®, Dream® Hotels, The StandardX, Breathless Resorts & Spas®, JdV by Hyatt®, Bunkhouse® Hotels, and Me and All Hotels; the Inclusive Collection, including Zoëtry® Wellness & Spa Resorts, Hyatt Ziva®, Hyatt Zilara®, Secrets® Resorts & Spas, Dreams® Resorts & Spas, Hyatt Vivid® Hotels & Resorts, Sunscape® Resorts & Spas, Alua Hotels & Resorts®, and Bahia Principe Hotels & Resorts; the Classics Portfolio, including Grand Hyatt®, Hyatt Regency®, Destination by Hyatt®, Hyatt Centric®, Hyatt Vacation Club®, and Hyatt®; and the Essentials Portfolio, including Caption by Hyatt®, Unscripted by Hyatt, Hyatt Place®, Hyatt House®, Hyatt Studios®, Hyatt Select, and UrCove. Subsidiaries of the Company operate the World of Hyatt® loyalty program, ALG Vacations®, Mr & Mrs Smith, Unlimited Vacation Club®, Amstar® DMC destination management services, and Trisept Solutions® technology services. For more information, please visit www.hyatt.com.

About Hyatt Centric

Hyatt Centric is a brand of full-service modern boutique hotels located in prime destinations. Created to connect guests to the heart of the action, Hyatt Centric hotels are thoughtfully designed to enable exploration and discovery so travelers never miss a moment of adventure. Each hotel offers social spaces to connect with others in the lobby, meanwhile the bar and restaurant are local hot spots where great conversations, locally inspired food and signature cocktails can be enjoyed. Streamlined contemporary rooms focus on delivering everything guests want and nothing they don’t. A passionately engaged team is there to provide local expertise on the best food, nightlife and activities the destination has to offer. For more information, please visit hyattcentric.com. Follow @HyattCentric on Facebook and Instagram, and tag photos with #HyattCentric.

About Interlink

Founded in 1977, Interlink is an integrated real estate company with more than four decades of experience in Puerto Rico and the Caribbean. Its primary focus is development, construction and management of assets and properties, within the residential, commercial and hospitality sectors. Interlink has a proven track record that includes an extensive portfolio of world-class developments and renowned construction projects. For more information you can visit: www.interlinkpr.com.

About Vivo Beach Club

Opened in 2017, the VIVO Beach Club resort offers an impressive array of “island living” experiences and beachfront entertainment. It’s a vibrant beachfront destination designed for people of all ages, featuring a beach club and outdoor pool, upscale restaurants and bars, a convention center, shops, music venues, and a craft brewery. It has established itself as one of the best day and night clubs in the metropolitan area, as well as the ideal place for private parties, large celebrations, festivals, concerts and corporate events. It is located on one of the best beaches in the world and offers a modern atmosphere with excellent gastronomy, drinks, shops, music and sea views. All the perfect ingredients for a great Caribbean experience.

Within the VIVO Beach Club complex is Ocean Lab Brewing Co., Puerto Rico’s largest craft beer maker, offering a wide variety of beer styles and activities. Ocean Lab Brewing recently received the award for Best Beer Bar in the United States.

Media Contacts:

Bianca Flores

Hyatt

[email protected]

Nelly Cruz

[email protected]

KEYWORDS: Illinois Latin America North America United States Puerto Rico Caribbean

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Interior Design Other Travel Architecture Lodging Vacation Other Construction & Property Destinations Travel

MEDIA:

Photo
Photo
Lobby & Espresso Lab
Photo
Photo
Pool Deck
Photo
Photo
Deluxe King Guestroom
Photo
Photo
Vivo Beach Club
Logo
Logo

GoDaddy Teams Up with Prime Video to Celebrate the Fallout Series Premiere

PR Newswire

GoDaddy Airo Powers an Interactive Digital Wasteland Experience for Fans

TEMPE, Ariz., Dec. 17, 2025 /PRNewswire/ — GoDaddy (NYSE: GDDY) is bringing an exciting online experience to fans of the Fallout series on Prime Video just in time for Season Two premiering on December 17. Through GoDaddy Airo®, fans can now explore a digital version of Ma June’s Sundries, the infamous trading post and cornerstone of survival in The Wasteland.

This collaboration gives fans a deeper look at The Wasteland’s pioneering entrepreneur, Ma June, and showcases how GoDaddy Airo transformed Ma June’s Sundries from a singular trading post into an interactive digital destination by simply starting with a domain. Visit godaddy.com/fallout to explore the digital storefront and learn about Airo’s capabilities by trying your hand at setting up your own business through an interactive experience.

“We’re throwing open the vault doors and inviting fans to carve out their own destiny in the digital Wasteland,” said GoDaddy’s Small Business Trends Expert Amy Jennette. “With Airo™, Fallout fans can channel their inner survivor—building a one-of-a-kind business inspired by Ma June’s grit, all from the comfort of their Pip-Boy. If you’ve survived The Wasteland, you can thrive online.” 

Based on one of the greatest video game series of all time, Fallout is the story of haves and have-nots in a world in which there’s almost nothing left to have. Two-hundred years after the apocalypse, the gentle denizens of luxury fallout shelters are forced to return to the irradiated hellscape their ancestors left behind—and are shocked to discover an incredibly complex, gleefully weird, and highly violent universe waiting for them. The new season will pick up in the aftermath of Season One’s epic finale and take audiences along for a journey through the wasteland of the Mojave to the post-apocalyptic city of New Vegas. Fallout Season Two premieres December 17 exclusively on Prime Video.

The series stars Ella Purnell (Yellowjackets, Sweetpea), Aaron Moten (Emancipation, Father Stu), Walton Goggins (The White Lotus, The Righteous Gemstones), Kyle MacLachlan (Twin Peaks), Moisés Arias (The King of Staten Island), and Frances Turner (The Boys).

Fallout is produced by Kilter Films, with executive producers Jonathan Nolan, Lisa Joy and Athena Wickham. Geneva Robertson-Dworet and Graham Wagner serve as executive producers, creators, and showrunners. Todd Howard, Bethesda Game Studios, executive produces along with James Altman for Bethesda Softworks. Margot Lulick also executive produces. Amazon MGM Studios and Kilter Films produce in association with Bethesda Game Studios and Bethesda Softworks.

About GoDaddy

GoDaddy helps millions of entrepreneurs globally start, grow, and scale their businesses. People come to GoDaddy to name their idea, build a website and logo, sell their products and services and accept payments. GoDaddy Airo®, the company’s AI-powered experience, makes growing a small business faster and easier by helping them to get their idea online in minutes, drive traffic and boost sales. GoDaddy’s expert guides are available 24/7 to provide assistance. To learn more about the company, visit www.GoDaddy.com.

Source: GoDaddy Inc.

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/godaddy-teams-up-with-prime-video-to-celebrate-the-fallout-series-premiere-302644841.html

SOURCE GoDaddy Inc.